RyboDyn Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.3M
- Investors
-
9
RyboDyn General Information
Description
Developer of an artificial intelligence (AI)-powered sequencing and discovery platform designed to decode the dark proteome for immunotherapy development. The company's technology utilizes high-resolution RNA sequencing and machine learning models to uncover and validate disease-specific cryptic targets, enabling pharmaceutical and biotechnology partners to identify previously hidden biological signals and develop first-in-class antibody therapeutics for cancer and autoimmune diseases.
Contact Information
Website
www.rybodyn.comCorporate Office
- 10935 Alexandria Way
- Suite 204
- San Diego, CA 92121
- United States
Corporate Office
- 10935 Alexandria Way
- Suite 204
- San Diego, CA 92121
- United States
RyboDyn Timeline
RyboDyn Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 09-Jul-2026 | $1.3M | Completed | Generating Revenue | ||
| 3. Seed Round | 24-Mar-2026 | Completed | Generating Revenue | |||
| 2. Seed Round | 09-Jan-2025 | $3.87M | $3.87M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
RyboDyn Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | 1,057,082 | $0.000100 | $0.24 | $0.24 | 1x | $0.24 | 2.58% | |
| Seed-2 | 2,817,622 | $0.000100 | $0.1 | $0.1 | 1x | $0.1 | 6.89% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
RyboDyn Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RyboDyn Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
RyboDyn Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of War | Government | |||
| Massive Tech Ventures | Venture Capital | Minority | ||
| Genedant Capital | Venture Capital | Minority | ||
| IndieBio | Accelerator/Incubator | Minority | ||
| Phase Two Ventures | Venture Capital | Minority |
RyboDyn FAQs
-
When was RyboDyn founded?
RyboDyn was founded in 2022.
-
Where is RyboDyn headquartered?
RyboDyn is headquartered in San Diego, CA.
-
What is the size of RyboDyn?
RyboDyn has 10 total employees.
-
What industry is RyboDyn in?
RyboDyn’s primary industry is Drug Discovery.
-
Is RyboDyn a private or public company?
RyboDyn is a Private company.
-
What is RyboDyn’s current revenue?
The current revenue for RyboDyn is .
-
How much funding has RyboDyn raised over time?
RyboDyn has raised $13.9M.
-
Who are RyboDyn’s investors?
United States Department of War, Massive Tech Ventures, Genedant Capital, IndieBio, and Phase Two Ventures are 5 of 9 investors who have invested in RyboDyn.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
